|
covid-19 |
80 |
|
sars-cov-2 |
70 |
|
influenza |
66 |
|
epidemiology |
41 |
|
transmission |
37 |
|
vaccination |
35 |
|
public health |
33 |
|
humans |
30 |
|
adult |
29 |
|
hong kong |
29 |
|
children |
27 |
|
child |
23 |
|
hong kong - epidemiology |
23 |
|
antibody |
22 |
|
pandemics |
22 |
|
surveillance |
22 |
|
vaccine effectiveness |
22 |
|
adolescent |
21 |
|
aged |
21 |
|
female |
21 |
|
coronavirus |
20 |
|
middle aged |
20 |
|
child, preschool |
19 |
|
coronavirus infection |
19 |
|
disease burden |
19 |
|
infection |
19 |
|
influenza virus |
19 |
|
coronavirus disease |
18 |
|
china |
17 |
|
disease outbreaks |
17 |
|
immunity |
17 |
|
male |
17 |
|
medical sciences |
17 |
|
transmissibility |
17 |
|
hospitalization |
16 |
|
infant |
16 |
|
omicron |
16 |
|
25-hydroxyvitamin d |
15 |
|
cross-sectional studies |
15 |
|
disease surveillance |
15 |
|
influenza a virus, h1n1 subtype - isolation and purification |
15 |
|
pandemic |
15 |
|
reproduction number |
15 |
|
severity |
15 |
|
viral shedding |
15 |
|
complications |
14 |
|
coronavirus disease 2019 |
14 |
|
death |
14 |
|
health outcomes |
14 |
|
influenza a(h7n9) |
14 |
|
influenza, human - mortality |
14 |
|
seasonal influenza |
14 |
|
asymptomatic |
13 |
|
chinese |
13 |
|
human influenza |
13 |
|
impact |
13 |
|
models, biological |
13 |
|
prospective studies |
13 |
|
vaccine |
13 |
|
antibodies, viral - blood |
12 |
|
cohort studies |
12 |
|
control |
12 |
|
disease transmission |
12 |
|
epidemic |
12 |
|
immunogenicity |
12 |
|
infectiousness |
12 |
|
influenza vaccine |
12 |
|
markov chains |
12 |
|
mortality |
12 |
|
neutralization tests |
12 |
|
regression analysis |
12 |
|
seasonality |
12 |
|
serology |
12 |
|
seroprevalence |
12 |
|
2019 novel coronavirus disease |
11 |
|
acute respiratory illness |
11 |
|
aged, 80 and over |
11 |
|
communicable disease control - methods |
11 |
|
monte carlo method |
11 |
|
population surveillance |
11 |
|
prediction |
11 |
|
quarantine |
11 |
|
symptoms |
11 |
|
age distribution |
10 |
|
all-cause pneumonia |
10 |
|
atrial fibrillation |
10 |
|
cause of death |
10 |
|
disparities |
10 |
|
family characteristics |
10 |
|
genetic polymorphism |
10 |
|
herd immunity |
10 |
|
incidence |
10 |
|
influenza a virus, h1n1 subtype - immunology - isolation and purification - pathogenicity |
10 |
|
interrupted time series analysis |
10 |
|
intervention |
10 |
|
meta-analysis |
10 |
|
patient admission - statistics and numerical data |
10 |
|
pneumococcal conjugate vaccines |
10 |
|
population-based electronic health records |
10 |
|
seasons |
10 |
|
socioeconomic |
10 |
|
vitamin d-binding protein |
10 |
|
work from home |
10 |
|
2009 h1n1 influenza |
9 |
|
airborne |
9 |
|
antibody titer |
9 |
|
avian influenza |
9 |
|
avian influenza a(h7n9) |
9 |
|
breast cancer |
9 |
|
cohort analysis |
9 |
|
contamination |
9 |
|
coughing |
9 |
|
disease outbreaks - statistics & numerical data |
9 |
|
excess mortality |
9 |
|
family health |
9 |
|
human |
9 |
|
immunoglobulin g - blood |
9 |
|
infant, newborn |
9 |
|
influenza a virus, h1n1 subtype - immunology |
9 |
|
influenza, human - epidemiology - immunology - virology |
9 |
|
influenza, human - epidemiology - prevention and control - virology |
9 |
|
influenza-virus |
9 |
|
mass testing |
9 |
|
population surveillance - methods |
9 |
|
reproducibility of results |
9 |
|
retrospective studies |
9 |
|
seroepidemiologic studies |
9 |
|
test-negative design |
9 |
|
transmission dynamics |
9 |
|
travel |
9 |
|
young adult |
9 |
|
age factors |
8 |
|
airborne transmission |
8 |
|
antibody-dependent cellular cytotoxicity |
8 |
|
antiviral |
8 |
|
attitudes |
8 |
|
baseline immunity |
8 |
|
behavior change |
8 |
|
bioaerosol |
8 |
|
cardiovascular |
8 |
|
chemicals and cas registry numbers |
8 |
|
controlled study |
8 |
|
disease predisposition |
8 |
|
elderly care |
8 |
|
face masks |
8 |
|
ha stem antibodies |
8 |
|
human exhaled breath |
8 |
|
humidity |
8 |
|
incidence rates |
8 |
|
influenza a virus |
8 |
|
influenza virus infection |
8 |
|
influenza-like illness |
8 |
|
mask |
8 |
|
oseltamivir |
8 |
|
pandemic h1n1 |
8 |
|
pandemics - statistics and numerical data |
8 |
|
respiratory infections |
8 |
|
school |
8 |
|
schools |
8 |
|
seroepidemiology |
8 |
|
statistics |
8 |
|
superspreading |
8 |
|
systematic review |
8 |
|
t cells |
8 |
|
testosterone |
8 |
|
time factors |
8 |
|
universal immune correlate |
8 |
|
airborne particles |
7 |
|
anthropometry - methods |
7 |
|
antibodies |
7 |
|
antiviral agents - therapeutic use |
7 |
|
asian continental ancestry group - statistics & numerical data |
7 |
|
awareness |
7 |
|
basic reproduction number |
7 |
|
body mass index |
7 |
|
burden |
7 |
|
carbapenemase-producing enterobacteriaceae |
7 |
|
carriage |
7 |
|
clinical epidemiology |
7 |
|
cluster |
7 |
|
communicable diseases, emerging - prevention and control - transmission |
7 |
|
confidence intervals |
7 |
|
contact tracing |
7 |
|
cost-effectiveness analysis |
7 |
|
disease severity |
7 |
|
effectiveness |
7 |
|
enterovirus |
7 |
|
ferrets |
7 |
|
importation |
7 |
|
incubation period |
7 |
|
influenza a virus, h1n1 subtype |
7 |
|
influenza a virus, h7n9 subtype |
7 |
|
influenza a(h5n1) |
7 |
|
influenza b |
7 |
|
influenza in birds - prevention and control - transmission |
7 |
|
influenza vaccines |
7 |
|
influenza, human - epidemiology - prevention & control - transmission |
7 |
|
influenza, human - prevention and control - transmission |
7 |
|
live poultry markets |
7 |
|
models, statistical |
7 |
|
nested case-control study |
7 |
|
nose - virology |
7 |
|
orthomyxoviridae - isolation & purification |
7 |
|
pharynx - virology |
7 |
|
reproductive number |
7 |
|
reverse transcriptase polymerase chain reaction |
7 |
|
risk factor |
7 |
|
screening |
7 |
|
treatment outcome |
7 |
|
united kingdom |
7 |
|
variant |
7 |
|
viral load |
7 |
|
age |
6 |
|
aging - physiology |
6 |
|
air travel-related outbreak |
6 |
|
albuminuria |
6 |
|
animals |
6 |
|
antibodies, neutralizing - blood |
6 |
|
antimicrobial stewardship |
6 |
|
avian influenza a (h7n9) |
6 |
|
behavior |
6 |
|
bnt162b2 |
6 |
|
breast cancer screening |
6 |
|
building ventilation |
6 |
|
burden of disease |
6 |
|
case clusters |
6 |
|
china - epidemiology |
6 |
|
chinese adults |
6 |
|
chinese medicine |
6 |
|
clinical diagnosis |
6 |
|
clinical prediction rule |
6 |
|
clinical trial |
6 |
|
computer simulation |
6 |
|
corticosteroids |
6 |
|
cost effectiveness |
6 |
|
cross protection |
6 |
|
decision aid |
6 |
|
disease transmission control |
6 |
|
dose fractionation |
6 |
|
droplet |
6 |
|
elisa |
6 |
|
environment |
6 |
|
enzyme linked immunosorbent assay |
6 |
|
epidemiological monitoring |
6 |
|
feces - virology |
6 |
|
generation time |
6 |
|
genetic variation |
6 |
|
genomic diversity |
6 |
|
genomic epidemiology |
6 |
|
glomerular filtration rate |
6 |
|
h1n1 pandemic |
6 |
|
h7n9 subtype |
6 |
|
health knowledge, attitudes, practice |
6 |
|
health status |
6 |
|
healthcare resource |
6 |
|
hemagglutination inhibition tests |
6 |
|
hemagglutinin glycoproteins, influenza virus - genetics |
6 |
|
high-rise buildings |
6 |
|
hospital emergency setting |
6 |
|
hospitalisation |
6 |
|
immune response |
6 |
|
immunization (vaccination) |
6 |
|
imported case |
6 |
|
infection control |
6 |
|
infectious disease outbreak |
6 |
|
influenza a |
6 |
|
influenza a virus, h1n1 subtype - classification - genetics - isolation & purification |
6 |
|
influenza a virus, h1n1 subtype - physiology |
6 |
|
influenza a virus, h3n2 subtype - classification - genetics - isolation & purification |
6 |
|
influenza a virus, h9n2 subtype - isolation & purification |
6 |
|
influenza b virus |
6 |
|
influenza in birds - mortality - transmission |
6 |
|
influenza vaccines - administration & dosage - immunology |
6 |
|
influenza, human - blood - epidemiology - virology |
6 |
|
influenza, human - epidemiology - prevention & control - virology |
6 |
|
influenza, human - epidemiology - prevention and control |
6 |
|
influenza, human - epidemiology - prevention and control - psychology - virology |
6 |
|
influenza, human - epidemiology - transmission - virology |
6 |
|
influenza, human - epidemiology - virology |
6 |
|
interventions |
6 |
|
isolation |
6 |
|
latent class analysis |
6 |
|
line list |
6 |
|
molecular sequence data |
6 |
|
neuraminidase - genetics |
6 |
|
non-pharmaceutical interventions |
6 |
|
odds ratio |
6 |
|
omicron variants |
6 |
|
pandemic preparedness |
6 |
|
pandemic responses |
6 |
|
phylodynamics |
6 |
|
phylogeny |
6 |
|
placebos - administration & dosage |
6 |
|
pneumonia admission |
6 |
|
population aging |
6 |
|
poultry - virology |
6 |
|
pragmatic |
6 |
|
pregnancy |
6 |
|
prescribing |
6 |
|
proportional hazards models |
6 |
|
protection |
6 |
|
protective behaviors |
6 |
|
psychological and behavioral responses |
6 |
|
residence characteristics |
6 |
|
residence characteristics - statistics and numerical data |
6 |
|
respiration, artificial - statistics and numerical data |
6 |
|
respiratory tract infections |
6 |
|
review |
6 |
|
risk perception |
6 |
|
rna, viral - genetics - isolation & purification |
6 |
|
rsv |
6 |
|
sensitivity |
6 |
|
sequence variation |
6 |
|
seriousness |
6 |
|
severe acute respiratory syndrome coronavirus 2 |
6 |
|
solar radiation |
6 |
|
specificity |
6 |
|
surface |
6 |
|
survival rate - trends |
6 |
|
tuberculosis - epidemiology |
6 |
|
vaccination - methods |
6 |
|
vaccines, inactivated - administration & dosage - immunology |
6 |
|
victoria lineage |
6 |
|
viral loads |
6 |
|
viral proteins - genetics |
6 |
|
virus shedding |
6 |
|
vitamin d |
6 |
|
waning |
6 |
|
whole genome sequencing |
6 |
|
yamagata lineage |
6 |
|
a(h7n9) |
5 |
|
absenteeism |
5 |
|
adiposity |
5 |
|
adjuvant |
5 |
|
air-sampler |
5 |
|
algorithms |
5 |
|
antibiotics |
5 |
|
antibody response |
5 |
|
antimicrobial resistance |
5 |
|
antivirals |
5 |
|
anxiety disorder |
5 |
|
atherosclerosis |
5 |
|
b cell |
5 |
|
betacoronavirus |
5 |
|
birth weight |
5 |
|
body height - physiology |
5 |
|
body weight - physiology |
5 |
|
booster dose |
5 |
|
breast neoplasms - diagnosis - prevention & control |
5 |
|
cancer |
5 |
|
cervical cancer |
5 |
|
checklist |
5 |
|
chicken |
5 |
|
child development |
5 |
|
child health |
5 |
|
children. |
5 |
|
chinese medicine;multi-centre |
5 |
|
civil disorder |
5 |
|
climate |
5 |
|
cohort |
5 |
|
communicable diseases |
5 |
|
community-acquired infections |
5 |
|
coronavac |
5 |
|
covid-19 vaccine |
5 |
|
credible interval |
5 |
|
dalys |
5 |
|
dashboard |
5 |
|
data interpretation, statistical |
5 |
|
decision making |
5 |
|
detection |
5 |
|
diabetes mellitus - ethnology - etiology |
5 |
|
disease activity |
5 |
|
disease control |
5 |
|
dispersion parameter |
5 |
|
dissemination |
5 |
|
dynamics |
5 |
|
educational status |
5 |
|
emergency department |
5 |
|
emergency service, hospital - utilization |
5 |
|
environmental surveillance |
5 |
|
flu like syndrome |
5 |
|
forecasting |
5 |
|
genetic difference |
5 |
|
geographically weighted regression |
5 |
|
geography |
5 |
|
growth |
5 |
|
h1n1pdm09 |
5 |
|
h5n1 |
5 |
|
h5n6 |
5 |
|
h7n9 |
5 |
|
h7n9 influenza virus |
5 |
|
ha stem |
5 |
|
hand-foot-and-mouth disease (hfmd) |
5 |
|
health care surveys |
5 |
|
health policy |
5 |
|
health services accessibility |
5 |
|
hong kong chinese |
5 |
|
hospitals |
5 |
|
hospitals, public - utilization |
5 |
|
human density |
5 |
|
iatrogenesis |
5 |
|
iatrogenic disease - epidemiology |
5 |
|
illness |
5 |
|
infant welfare |
5 |
|
infectious disease |
5 |
|
influenza a (h1n1) |
5 |
|
influenza a virus - physiology |
5 |
|
influenza and respiratory viruses |
5 |
|
influenza b virus - physiology |
5 |
|
influenza virus a h9n2 |
5 |
|
influenza, human - diagnosis - epidemiology |
5 |
|
influenza, human - diagnosis - virology |
5 |
|
influenza, human - drug therapy - transmission - virology |
5 |
|
influenza, human - epidemiology - prevention and control - transmission |
5 |
|
influenza, human - pathology - virology |
5 |
|
informed choice |
5 |
|
informed decision |
5 |
|
inhalation |
5 |
|
interferons |
5 |
|
isolation delays |
5 |
|
knowledge |
5 |
|
leg - anatomy & histology |
5 |
|
length of stay |
5 |
|
lineage specific |
5 |
|
linear models |
5 |
|
lipids - chemistry |
5 |
|
live poultry trader |
5 |
|
longitudinal |
5 |
|
mammography - economics |
5 |
|
mass screening - utilization |
5 |
|
maternal |
5 |
|
maternal welfare |
5 |
|
medical geography |
5 |
|
medical sciences public health and safety |
5 |
|
menarche |
5 |
|
metabolic syndrome x - diagnosis - epidemiology - etiology - physiopathology |
5 |
|
multivariate analysis |
5 |
|
neuraminidase inhibitors |
5 |
|
non-influenza respiratory virus |
5 |
|
non-influenza respiratory virus infection |
5 |
|
nonlinear dynamics |
5 |
|
nonpharmaceutical interventions |
5 |
|
obesity |
5 |
|
orthomyxoviridae - isolation and purification |
5 |
|
oseltamivir - therapeutic use |
5 |
|
outpatient |
5 |
|
overweight - epidemiology - etiology |
5 |
|
patient admission - statistics & numerical data |
5 |
|
physical examination |
5 |
|
population density |
5 |
|
population-based cohort |
5 |
|
protective behaviours |
5 |
|
questionnaires |
5 |
|
r292k na mutation |
5 |
|
randomized controlled trial |
5 |
|
reference values |
5 |
|
references (9) view in table layout |
5 |
|
registry |
5 |
|
resistance |
5 |
|
respiratory syncytial virus (rsv) |
5 |
|
risk |
5 |
|
risk assessment |
5 |
|
risk factors |
5 |
|
school vaccination policy |
5 |
|
self-assessment |
5 |
|
self-examination - methods |
5 |
|
sentinel surveillance |
5 |
|
serial interval |
5 |
|
serial intervals |
5 |
|
severe outcomes |
5 |
|
sex characteristics |
5 |
|
smoking - mortality |
5 |
|
social conditions - statistics & numerical data |
5 |
|
social norms |
5 |
|
socioeconomic factors |
5 |
|
susceptibility |
5 |
|
symptom |
5 |
|
systematic review and meta-analysis |
5 |
|
temporal pattern |
5 |
|
temporary protection |
5 |
|
tobacco medical sciences |
5 |
|
trajectory |
5 |
|
triavalent influenza vaccine |
5 |
|
uterine cervical neoplasms - diagnosis - prevention & control |
5 |
|
vaccination policy assessment |
5 |
|
vaccination uptake |
5 |
|
vaccine efficacy |
5 |
|
vaccine hesitancy |
5 |
|
vaccine match |
5 |
|
vaccine pass |
5 |
|
vaccine passport |
5 |
|
vaccine refusal |
5 |
|
vaccine uptake |
5 |
|
virus interference |
5 |
|
world health organization |
5 |
|
acceptability |
4 |
|
acute liver injury |
4 |
|
acute respiratory infections |
4 |
|
adaptive immunity |
4 |
|
adrenal cortex hormones - therapeutic use |
4 |
|
affect |
4 |
|
affective feelings |
4 |
|
age differences |
4 |
|
andersen-gill model |
4 |
|
androgen |
4 |
|
anti-neuraminidase antibody |
4 |
|
antibiotic resistance genes |
4 |
|
antigenic cartography |
4 |
|
antigens, viral - analysis |
4 |
|
anxiety |
4 |
|
asian continental ancestry group - statistics and numerical data |
4 |
|
asymptomatic cases |
4 |
|
behavior therapy |
4 |
|
biocide resistance genes |
4 |
|
biostatistics |
4 |
|
bivalent rna vaccine |
4 |
|
body height |
4 |
|
border control |
4 |
|
breast neoplasms - diagnosis - economics - ethnology |
4 |
|
breast neoplasms - ethnology |
4 |
|
breast neoplasms - prevention & control - radiotherapy - surgery - therapy |
4 |
|
canada - epidemiology |
4 |
|
cancer care |
4 |
|
cardiovascular diseases |
4 |
|
case series |
4 |
|
cholesterol |
4 |
|
cities - epidemiology |
4 |
|
clinical trials |
4 |
|
cognitive processes |
4 |
|
comirnaty |
4 |
|
communicable diseases, emerging - epidemiology |
4 |
|
communicable diseases, emerging - epidemiology - prevention and control |
4 |
|
communication |
4 |
|
contact tracing - methods |
4 |
|
correlate of protection |
4 |
|
correlation |
4 |
|
cost-benefit analysis |
4 |
|
covid‐19 |
4 |
|
cross-reactive antibody |
4 |
|
daily life activity |
4 |
|
delivery |
4 |
|
depression |
4 |
|
determinants |
4 |
|
developed countries |
4 |
|
developing countries |
4 |
|
diabetes |
4 |
|
diabetes mellitus, type 2 - epidemiology |
4 |
|
diagnostic tests |
4 |
|
digital rt-pcr |
4 |
|
dpp4i |
4 |
|
droplet transmission |
4 |
|
drug administration schedule |
4 |
|
drug therapy, combination |
4 |
|
early detection of cancer - economics |
4 |
|
economic development |
4 |
|
effective reproduction number |
4 |
|
emigrants and immigrants |
4 |
|
epidemiologic methods |
4 |
|
extended dosing interval |
4 |
|
face mask |
4 |
|
follow-up studies |
4 |
|
fomite |
4 |
|
guangdong |
4 |
|
gut microbiome |
4 |
|
h1n1 |
4 |
|
h2 |
4 |
|
hand sanitizer |
4 |
|
handwashing |
4 |
|
hazard of infection |
4 |
|
health benefit plans, employee - economics - statistics & numerical data |
4 |
|
health care rationing - economics |
4 |
|
health care workers |
4 |
|
health insurance |
4 |
|
health services |
4 |
|
health services needs and demand |
4 |
|
healthcare seeking behaviour |
4 |
|
healthcare workers |
4 |
|
hemagglutination inhibition |
4 |
|
hemagglutinin-stalk |
4 |
|
households |
4 |
|
hygiene |
4 |
|
hygiene - personal |
4 |
|
hyperinflammatory syndrome |
4 |
|
immune evasion |
4 |
|
immunoassay |
4 |
|
immunoassay - methods |
4 |
|
imported cases |
4 |
|
in-hospital death |
4 |
|
in-hospital mortality |
4 |
|
indirect contact |
4 |
|
infection-naïve |
4 |
|
inflammation |
4 |
|
influenza a virus - genetics - immunology - isolation and purification |
4 |
|
influenza a virus - immunology - isolation and purification |
4 |
|
influenza a virus - isolation & purification |
4 |
|
influenza a virus, h1n1 subtype - genetics - immunology - isolation and purification |
4 |
|
influenza a virus, h1n1 subtype - isolation & purification |
4 |
|
influenza a virus, h5n1 subtype |
4 |
|
influenza activity |
4 |
|
influenza b virus - immunology - isolation and purification |
4 |
|
influenza b virus - isolation & purification |
4 |
|
influenza in birds - epidemiology - prevention and control |
4 |
|
influenza pandemic |
4 |
|
influenza transmission |
4 |
|
influenza vaccines - administration and dosage - immunology |
4 |
|
influenza vaccines - adverse effects - immunology - supply and distribution |
4 |
|
influenza virus a h1n1 |
4 |
|
influenza, human - complications - epidemiology - mortality |
4 |
|
influenza, human - diagnosis - epidemiology - transmission |
4 |
|
influenza, human - diagnosis - prevention & control - transmission |
4 |
|
influenza, human - epidemiology - immunology - prevention and control |
4 |
|
influenza, human - epidemiology - prevention and control - transmission - virology |
4 |
|
influenza, human - microbiology - prevention and control |
4 |
|
influenza‐like illness |
4 |
|
information dissemination |
4 |
|
insurance, health - economics - statistics & numerical data |
4 |
|
intensive care unit |
4 |
|
intention |
4 |
|
interim |
4 |
|
internet |
4 |
|
iodine radioisotopes - therapeutic use |
4 |
|
isotemporal substitution |
4 |
|
l-lactate dehydrogenase |
4 |
|
letter |
4 |
|
life expectancy |
4 |
|
life table |
4 |
|
mammography |
4 |
|
masks |
4 |
|
masks - statistics and numerical data |
4 |
|
mass screening - economics - methods |
4 |
|
mass screening - methods |
4 |
|
men |
4 |
|
mobile phone |
4 |
|
mode of transmission |
4 |
|
models, theoretical |
4 |
|
monitoring |
4 |
|
monoclonal antibody |
4 |
|
moral hazard |
4 |
|
morals |
4 |
|
motor activity - physiology |
4 |
|
mrna vaccine |
4 |
|
neoplasm staging |
4 |
|
neoplasms, second primary - epidemiology |
4 |
|
neutralization |
4 |
|
news sentiment |
4 |
|
nirmatrelvir/ritonavir |
4 |
|
non-pharmaceutical intervention |
4 |
|
obesity - epidemiology |
4 |
|
object |
4 |
|
older adults |
4 |
|
omicron subvariant |
4 |
|
online systems |
4 |
|
ontario - epidemiology |
4 |
|
orthomyxoviridae - immunology - isolation and purification |
4 |
|
out-of-hospital mortality |
4 |
|
paediatrics |
4 |
|
palliative care |
4 |
|
pandemic a ⁄ h1n1 |
4 |
|
pandemic influenza |
4 |
|
pandemic risk assessment |
4 |
|
pandemics - prevention and control |
4 |
|
parametric bootstrap |
4 |
|
parental decision |
4 |
|
patient compliance |
4 |
|
patient education as topic |
4 |
|
pattern |
4 |
|
pediatrics |
4 |
|
perceived risk |
4 |
|
perception |
4 |
|
personal hygiene practices |
4 |
|
physical activity |
4 |
|
pneumonia |
4 |
|
policy making |
4 |
|
population mental health |
4 |
|
predict |
4 |
|
preexisting immunity |
4 |
|
prevalence |
4 |
|
prevention |
4 |
|
prognosis |
4 |
|
projection |
4 |
|
propensity score |
4 |
|
prospective study |
4 |
|
protective behavior |
4 |
|
protective effectiveness |
4 |
|
psychological distress |
4 |
|
psychosocial factors |
4 |
|
public health and safety |
4 |
|
quality-adjusted life years |
4 |
|
reactogenicity |
4 |
|
reagent kits, diagnostic |
4 |
|
references (20) view in table layout |
4 |
|
references (39) view in table layout |
4 |
|
registries - statistics & numerical data |
4 |
|
repeated vaccination |
4 |
|
resource allocation |
4 |
|
respiratory distress syndrome, adult - drug therapy - mortality |
4 |
|
respiratory mortality |
4 |
|
respiratory virus |
4 |
|
ribavirin |
4 |
|
ribavirin - therapeutic use |
4 |
|
roc curve |
4 |
|
rt-pcr |
4 |
|
sars‐cov‐2 |
4 |
|
school absenteeism |
4 |
|
school attendance |
4 |
|
school-located influenza vaccination |
4 |
|
seasonal |
4 |
|
seasonal h1n1 |
4 |
|
secular trend |
4 |
|
sedentary behaviour |
4 |
|
self report |
4 |
|
sero-diagnosis |
4 |
|
severe acute respiratory syndrome |
4 |
|
severe acute respiratory syndrome - epidemiology |
4 |
|
severe acute respiratory syndrome - epidemiology - mortality |
4 |
|
severe acute respiratory syndrome - epidemiology - transmission |
4 |
|
severity of illness index |
4 |
|
sickness absence |
4 |
|
sleep |
4 |
|
social vulnerability index |
4 |
|
social welfare - economics - statistics & numerical data |
4 |
|
social-cognitive |
4 |
|
socio-economic vulnerability |
4 |
|
statins |
4 |
|
statistics, nonparametric |
4 |
|
subsidy |
4 |
|
super-spreading event |
4 |
|
surveillance tolls |
4 |
|
swine influenza |
4 |
|
symptom-specific |
4 |
|
systematic reviews |
4 |
|
t cell |
4 |
|
target groups |
4 |
|
thyroid neoplasms - pathology - radiotherapy |
4 |
|
treatment |
4 |
|
trend |
4 |
|
trial |
4 |
|
trust in information |
4 |
|
tuberculosis - epidemiology - transmission |
4 |
|
uncertainty |
4 |
|
underlying risk factors |
4 |
|
universal vaccine |
4 |
|
vaccination acceptance |
4 |
|
vaccine acceptance |
4 |
|
viral clearance |
4 |
|
years of life lost |
4 |
|
young child |
4 |
|
accreditation |
3 |
|
aerosol |
3 |
|
aerosols |
3 |
|
aircraft |
3 |
|
amplicon |
3 |
|
antibiotic |
3 |
|
antiviral activity |
3 |
|
article |
3 |
|
asia-pacific |
3 |
|
asian continental ancestry group |
3 |
|
attitude to health |
3 |
|
baloxavir |
3 |
|
bayesian inference |
3 |
|
behaviour |
3 |
|
bioassay |
3 |
|
birth rate |
3 |
|
blood donor |
3 |
|
breast feeding |
3 |
|
breast milk |
3 |
|
breast neoplasms - economics - ethnology - prevention & control |
3 |
|
broadly neutralizing epitopes |
3 |
|
carbapenem resistance |
3 |
|
case-control |
3 |
|
cell differentiation |
3 |
|
chemical determination |
3 |
|
chimera |
3 |
|
chimeric hemagglutinin |
3 |
|
chronic disease |
3 |
|
clinical improvement |
3 |
|
clinical severity |
3 |
|
close-contact transmission |
3 |
|
communicable disease |
3 |
|
consensus sequence |
3 |
|
contact patterns |
3 |
|
convalescent |
3 |
|
correlation analysis |
3 |
|
cost |
3 |
|
coxsackie |
3 |
|
cruise ship |
3 |
|
ddd |
3 |
|
dde |
3 |
|
ddt |
3 |
|
ddt - analysis - metabolism |
3 |
|
deep learning |
3 |
|
delta |
3 |
|
demography |
3 |
|
diabetes mellitus |
3 |
|
dioxins |
3 |
|
dioxins - analysis |
3 |
|
disease duration |
3 |
|
disease outbreaks - prevention & control - statistics & numerical data |
3 |
|
durable b cell responses |
3 |
|
ebola virus |
3 |
|
economic aspect |
3 |
|
economic development - statistics & numerical data |
3 |
|
economic development - trends |
3 |
|
emigration and immigration - statistics & numerical data |
3 |
|
enterobacteriaceae |
3 |
|
environmental pollutants - analysis |
3 |
|
environmental pollutants - analysis - metabolism |
3 |
|
epidemiologic research design |
3 |
|
epidemiological model |
3 |
|
epstein-barr virus infections |
3 |
|
ev-a71 infection |
3 |
|
france |
3 |
|
gas chromatography-mass spectrometry |
3 |
|
genetic susceptibility |
3 |
|
genetic variability |
3 |
|
government |
3 |
|
ha anchor epitope |
3 |
|
ha stalk epitope |
3 |
|
hand hygiene |
3 |
|
health care cost |
3 |
|
health care personnel |
3 |
|
health service |
3 |
|
health status disparities |
3 |
|
health status indicators |
3 |
|
health transition |
3 |
|
healthcare personnel |
3 |
|
helicobacter pylori |
3 |
|
hepatitis b virus |
3 |
|
hfmd |
3 |
|
hong kong influenza |
3 |
|
hospital wastewater |
3 |
|
hospitalization - statistics & numerical data |
3 |
|
hospitals public |
3 |
|
household transmission |
3 |
|
human infection |
3 |
|
human papillomavirus |
3 |
|
human t lymphotropic virus |
3 |
|
human-to-human transmissibility |
3 |
|
immunization, passive |
3 |
|
income - classification |
3 |
|
income inequality |
3 |
|
infection control - methods |
3 |
|
infection-fatality risk |
3 |
|
infectious disease control |
3 |
|
infectious disease epidemiology |
3 |
|
infectious disease transmission, vertical - prevention and control |
3 |
|
influenza a (h3n2) |
3 |
|
influenza a virus, h1n1 subtype - pathogenicity |
3 |
|
influenza a virus, h3n2 subtype |
3 |
|
influenza lineage elimination |
3 |
|
influenza vaccination |
3 |
|
influenza, human - complications |
3 |
|
influenza, human - epidemiology |
3 |
|
influenza, human - epidemiology - immunology - prevention and control - therapy |
3 |
|
influenza, human - epidemiology - transmission |
3 |
|
interviews as topic |
3 |
|
ivig |
3 |
|
key words influenza |
3 |
|
klebsiella quasipneumoniae |
3 |
|
klebsiella spp. |
3 |
|
korea |
3 |
|
logistic models |
3 |
|
long term care |
3 |
|
longitudinal studies |
3 |
|
luciferases - analysis |
3 |
|
lung neoplasms - mortality |
3 |
|
masks - utilization |
3 |
|
maternal exposure |
3 |
|
mathematical model |
3 |
|
mendelian randomization |
3 |
|
methicillin resistance |
3 |
|
milk, human - chemistry |
3 |
|
molecular epidemiology |
3 |
|
mrsa |
3 |
|
myocardial infarction - complications - epidemiology - mortality |
3 |
|
myocardial ischemia |
3 |
|
myocardial ischemia - mortality |
3 |
|
neighbourhood |
3 |
|
neoplasms - epidemiology |
3 |
|
neoplasms, second primary - complications - epidemiology - mortality - radiotherapy |
3 |
|
neutralization assay |
3 |
|
neutralizing antibody level |
3 |
|
neutropenia |
3 |
|
neutropenic fever |
3 |
|
next-generation influenza vaccine |
3 |
|
next-generation sequencing |
3 |
|
nucleocapsid |
3 |
|
orthomyxoviridae |
3 |
|
outcome assessment (health care) |
3 |
|
pandemic h1n1 2009 |
3 |
|
phylogeography |
3 |
|
plasma |
3 |
|
plasma - immunology |
3 |
|
plasmapheresis |
3 |
|
poisson distribution |
3 |
|
policy implementation |
3 |
|
power |
3 |
|
pre-symptomatic |
3 |
|
priority journal |
3 |
|
prudent antimicrobial prescription |
3 |
|
public health service |
3 |
|
quality improvement |
3 |
|
rapid antigen detection kit |
3 |
|
real time quantitative rt-pcr |
3 |
|
reassortant virus |
3 |
|
remdesivir |
3 |
|
residence characteristics - classification - statistics & numerical data |
3 |
|
respiratory protective devices - utilization |
3 |
|
respiratory tract infections - epidemiology - transmission |
3 |
|
respiratory viruses |
3 |
|
sample size |
3 |
|
sars virus |
3 |
|
school closures |
3 |
|
school health service |
3 |
|
seasonal h1n1 and h3n2 |
3 |
|
secular trends |
3 |
|
self concept |
3 |
|
self-rated health |
3 |
|
severe acute respiratory syndrome - epidemiology - etiology - prevention & control |
3 |
|
severity profile |
3 |
|
sexually transmitted diseases - complications |
3 |
|
short- and long-term evolutionary dynamics |
3 |
|
social distance |
3 |
|
social distancing measure |
3 |
|
south-east asia |
3 |
|
standardization |
3 |
|
staphylococcus aureus |
3 |
|
stewardship |
3 |
|
symptomatic |
3 |
|
thyroid neoplasms - complications - epidemiology - mortality - pathology - radiotherapy - secondary - surgery |
3 |
|
toxic equivalent factor |
3 |
|
transients and migrants - statistics & numerical data |
3 |
|
translation to population health |
3 |
|
travel control |
3 |
|
universal influenza vaccine |
3 |
|
urban health - classification - statistics & numerical data |
3 |
|
vaccine booster |
3 |
|
vietnam |
3 |
|
viral genomic load |
3 |
|
virus a16 |
3 |
|
virus infection |
3 |
|
wgs |
3 |
|
a/h7n9 |
2 |
|
a/h9n2 |
2 |
|
accuracy |
2 |
|
adjuvant therapy |
2 |
|
adult infections |
2 |
|
aerosol transmission |
2 |
|
agent-based model |
2 |
|
anti-retroviral agents - therapeutic use |
2 |
|
antibody blood level |
2 |
|
antibody detectionanti |
2 |
|
antigenicity |
2 |
|
asian |
2 |
|
assortative mating |
2 |
|
asymptotically efficient |
2 |
|
attack rate |
2 |
|
b lymphocyte |
2 |
|
biomarkers |
2 |
|
biomedical research |
2 |
|
body titer |
2 |
|
braf mutation |
2 |
|
breathing disorder |
2 |
|
burnout |
2 |
|
care homes |
2 |
|
case control study |
2 |
|
case fatality risk |
2 |
|
causal inference |
2 |
|
central neck dissection |
2 |
|
clinical competence - standards |
2 |
|
clinical decision making |
2 |
|
clinical effectiveness |
2 |
|
clinical outcome |
2 |
|
clinical practice |
2 |
|
closure |
2 |
|
communicable diseases, emerging - mortality - transmission |
2 |
|
consultants - statistics & numerical data |
2 |
|
convalescence |
2 |
|
cost of illness |
2 |
|
covid |
2 |
|
cowling, b.j. |
2 |
|
data analysis |
2 |
|
data collection |
2 |
|
data collection - economics - methods |
2 |
|
dengue |
2 |
|
disaster planning |
2 |
|
disease notification - methods |
2 |
|
disease outbreaks - prevention & control |
2 |
|
disease spread |
2 |
|
disease transmission, infectious - prevention & control |
2 |
|
drug efficacy |
2 |
|
education |
2 |
|
effective education |
2 |
|
england |
2 |
|
environmental protection |
2 |
|
epidemics |
2 |
|
epidemiological control |
2 |
|
epidemiological parameters |
2 |
|
evidence based medicine |
2 |
|
evidence-based practice |
2 |
|
familial farm |
2 |
|
field epidemiologist |
2 |
|
fomite transmission |
2 |
|
gynecology - standards |
2 |
|
hajj |
2 |
|
hand washing |
2 |
|
health personnel |
2 |
|
healthcare settings |
2 |
|
heterogeneity |
2 |
|
hiv |
2 |
|
hiv - growth & development |
2 |
|
hiv infections - drug therapy - virology |
2 |
|
human contact |
2 |
|
hygiene criterion |
2 |
|
hypoparathyroidism |
2 |
|
ic50 |
2 |
|
imprinting protection |
2 |
|
infection prevention |
2 |
|
infection risk |
2 |
|
infectious diseases |
2 |
|
influenza vaccines - therapeutic use |
2 |
|
influenza viruses |
2 |
|
influenza, human - diagnosis - epidemiology - virology |
2 |
|
influenza, human - mortality - transmission - virology |
2 |
|
influenza, human - prevention & control - transmission |
2 |
|
interval-censored data |
2 |
|
intervention studies |
2 |
|
lateral flow assay |
2 |
|
likelihood functions |
2 |
|
lineage |
2 |
|
live poultry market |
2 |
|
lockdown |
2 |
|
long-range forecast |
2 |
|
malaysia |
2 |
|
masking |
2 |
|
maternal antibody |
2 |
|
mathematical modeling |
2 |
|
mathematical models |
2 |
|
mental health |
2 |
|
middle east respiratory syndrome coronavirus |
2 |
|
misconception |
2 |
|
netherlands |
2 |
|
network analysis |
2 |
|
neuraminidase inhibitor |
2 |
|
nonhealthcare settings |
2 |
|
nonhuman |
2 |
|
nonpharmaceutical measures |
2 |
|
nosocomial infections |
2 |
|
novel coronavirus diseases 2019 |
2 |
|
occupational stress |
2 |
|
omicron variant |
2 |
|
orthomyxoviridae - physiology |
2 |
|
outcome assessment |
2 |
|
papillary thyroid carcinoma |
2 |
|
partial linear model |
2 |
|
partially airborne route |
2 |
|
pediatric infections |
2 |
|
population incidence |
2 |
|
preference |
2 |
|
prevention and control |
2 |
|
primary prevention |
2 |
|
public health practice |
2 |
|
public transport |
2 |
|
rapid antigen test |
2 |
|
recurrent laryngeal nerve |
2 |
|
rest day |
2 |
|
sars-cov-2 infection |
2 |
|
school transmission |
2 |
|
seasonal flu |
2 |
|
seattle |
2 |
|
secondary attack rate |
2 |
|
sensitivity and specificity |
2 |
|
sieve maximum likelihood estimator |
2 |
|
social distancing |
2 |
|
south korea |
2 |
|
spatiotemporal |
2 |
|
statistical analysis |
2 |
|
surface cleaning |
2 |
|
swine movements |
2 |
|
temperature |
2 |
|
terminology as topi |
2 |
|
test negative design |
2 |
|
trainee |
2 |
|
training |
2 |
|
urban contact network |
2 |
|
urban population |
2 |
|
urbanization |
2 |
|
vaccination choice |
2 |
|
value chain |
2 |
|
ventilation |
2 |
|
ventilation requirement |
2 |
|
viral aerosols |
2 |
|
virology - methods |
2 |
|
virus isolation |
2 |
|
viruses |
2 |
|
world health |
2 |
|
wuhan |
2 |
|
zoonoses |
2 |
|
© medline® is the source for the citation and abstract of this record. |
2 |
|
'influenza vaccines' [mesh] |
1 |
|
'influenza, human' [mesh] |
1 |
|
'vaccination' [mesh] |
1 |
|
adherence |
1 |
|
aging |
1 |
|
animal husbandry |
1 |
|
anti-bacterial agent |
1 |
|
anti-retroviral agents - adverse effects - therapeutic use |
1 |
|
antibiotic resistance |
1 |
|
anticonvulsants - therapeutic use |
1 |
|
antiretroviral therapy, highly active |
1 |
|
antiviral agents - administration and dosage |
1 |
|
artificial ventilation |
1 |
|
asia, southeastern - epidemiology |
1 |
|
atherosclerosis - chemically induced - mortality |
1 |
|
bacterial gene |
1 |
|
bayesian statistics |
1 |
|
behavioral monitoring |
1 |
|
bronchiolitis |
1 |
|
bronchitis |
1 |
|
carbamazepine |
1 |
|
carbamazepine - therapeutic use |
1 |
|
causality |
1 |
|
cd4 lymphocyte count |
1 |
|
cefepime |
1 |
|
censored point process |
1 |
|
clinical practice research datalink |
1 |
|
clinical trial (topic) |
1 |
|
clonorchiasis |
1 |
|
communicable diseases - complications - epidemiology |
1 |
|
community |
1 |
|
comparative study |
1 |
|
computer games |
1 |
|
consensus |
1 |
|
correlates of protection |
1 |
|
cost effectiveness analysis |
1 |
|
covid-19 inactivated vaccines |
1 |
|
curve fitting |
1 |
|
databases, factual |
1 |
|
directed acyclic graphs |
1 |
|
disease outbreaks - statistics and numerical data |
1 |
|
disease progression |
1 |
|
distribution |
1 |
|
drug use |
1 |
|
ebola hemorrhagic fever |
1 |
|
effective reproduction numbers |
1 |
|
effective reproductive number |
1 |
|
efficiency |
1 |
|
electronic health record |
1 |
|
environmental exposure |
1 |
|
environmental temperature |
1 |
|
enzyme-linked immunosorbent assay |
1 |
|
epidemiologic studies |
1 |
|
epilepsies, partial - diagnosis - drug therapy |
1 |
|
epilepsy |
1 |
|
epilepsy - diagnosis - drug therapy |
1 |
|
erological evidence |
1 |
|
essential workers |
1 |
|
europe - epidemiology |
1 |
|
evaluation |
1 |
|
event rate |
1 |
|
filtration |
1 |
|
first responders |
1 |
|
fold-increase |
1 |
|
gender |
1 |
|
geographic distribution |
1 |
|
global disease burden |
1 |
|
hand, foot and mouth disease |
1 |
|
handwashing - methods |
1 |
|
health care-associated infections |
1 |
|
health education |
1 |
|
health promotion |
1 |
|
health surveys |
1 |
|
health workers |
1 |
|
hemagglutinin |
1 |
|
hengxian |
1 |
|
herpangina |
1 |
|
hiv infections - complications - drug therapy - mortality |
1 |
|
hiv infections - immunology - virology |
1 |
|
hiv protease inhibitors - adverse effects - therapeutic use |
1 |
|
hiv-1 |
1 |
|
household study |
1 |
|
households with children |
1 |
|
hygiene-personal |
1 |
|
immunology |
1 |
|
individual-level models |
1 |
|
infection prevention and control |
1 |
|
infection transmission |
1 |
|
infectious disease transmission, vertical - prevention & control |
1 |
|
infectivity |
1 |
|
influenza a (h7n9) |
1 |
|
influenza a virus - classification - isolation and purification |
1 |
|
influenza dynamics |
1 |
|
influenza in humans |
1 |
|
influenza, human - complications - epidemiology |
1 |
|
influenza, human - drug therapy - prevention and control |
1 |
|
influenza, human - drug therapy - prevention and control - transmission - virology |
1 |
|
influenza, human - prevention & control |
1 |
|
international |
1 |
|
interval censoring |
1 |
|
local transmission |
1 |
|
long covid |
1 |
|
long-range airborne route |
1 |
|
lower detection limit |
1 |
|
markov chain monte carlo |
1 |
|
mcmc |
1 |
|
middle east respiratory syndrome |
1 |
|
modeling |
1 |
|
modelling |
1 |
|
multi-route transmission |
1 |
|
nasopharynx - virology |
1 |
|
neuraminidase |
1 |
|
neuraminidase - antagonists and inhibitors |
1 |
|
notification |
1 |
|
observational studies |
1 |
|
occupational exposure |
1 |
|
occupational risk factors |
1 |
|
oseltamivir - administration and dosage |
1 |
|
pandemics - prevention & control |
1 |
|
parameter estimation |
1 |
|
personal protective equipment |
1 |
|
pooled estimates |
1 |
|
post-treatment variable |
1 |
|
potential outcomes |
1 |
|
poultry workers |
1 |
|
preventive medicine |
1 |
|
principal stratification |
1 |
|
promotional activities |
1 |
|
publicity campaign |
1 |
|
public–private partnerships |
1 |
|
recurrent event |
1 |
|
references (33) view in table layout |
1 |
|
respiratory infection |
1 |
|
respiratory medicine (see thoracic medicine) |
1 |
|
response |
1 |
|
reverse transcriptase inhibitors - adverse effects - therapeutic use |
1 |
|
sars-cov-2 elimination |
1 |
|
semicontinuous data |
1 |
|
sentinel |
1 |
|
serological evidence |
1 |
|
serum - virology |
1 |
|
sex distribution |
1 |
|
sex factors |
1 |
|
short-range airborne route |
1 |
|
simulation |
1 |
|
smoking |
1 |
|
sodium valproate |
1 |
|
survival analysis |
1 |
|
test-negative study |
1 |
|
test-negative study design |
1 |
|
thailand |
1 |
|
two-part random effects model |
1 |
|
united states |
1 |
|
videos |
1 |
|
virus transmission |
1 |
